Clinical Trial: Sufficient Treatment of Peripheral Intervention by Cilostazol

Study Status: Recruiting
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment

Brief Summary:

Recently, Nanto et al. reported that cilostazol effectively prevented restenosis in a retrospective analysis of 121 femoropopliteal artery lesions in percutaneous transluminal angioplasty (PTA) patients who had undergone PTA. In a prospective 3-year follow-up study in 127 patients with similar diseases, the patency rate was significantly higher in the cilostazol group than in the ticlopidine group. It was also found that cilostazol markedly inhibited restenosis during the first 1-year period following endovascular therapy when restenosis is most frequently observed. In addition, there have been sporadic reports that cilostazol was effective in preventing post-stenting restenosis in the coronary artery area.

Based on these results, this multicenter study is going to be conducted to prospectively evaluate the usefulness of cilostazol in lower limb endovascular therapy.

Detailed Summary:
Sponsor: Kansai Rosai Hospital

Current Primary Outcome: Angiographic restenosis rate [ Time Frame: 12 months +- 1 month ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Cardiovascular events

Original Secondary Outcome: Same as current

Information By: Kansai Rosai Hospital

Dates:
Date Received: June 2, 2009
Date Started: March 2009
Date Completion: September 2012
Last Updated: July 21, 2010
Last Verified: July 2010